Home » INFINITY ANNOUNCES EXTENSION OF AMGEN AGREEMENT
INFINITY ANNOUNCES EXTENSION OF AMGEN AGREEMENT
Infinity Pharmaceuticals Inc. announced that Amgen Inc. has extended its non-exclusive access to Infinity's collection of diverse, natural product-like compounds for drug discovery. Under the terms of the agreement, Amgen has the right to develop drug candidates it has identified from Infinity's compound collection. Infinity received an up-front license fee from Amgen and is eligible to receive milestones and royalties based on successful pre-clinical and clinical development and marketing of products resulting from Amgen's use of Infinity's compounds.
Yahoo Finance
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May